AI for Smarter Healthcare
Keya Medical is an international medical technology company developing deep learning-based medical devices for disease diagnosis and treatment. The company is committed to creating products that empower healthcare providers by optimizing efficiency, improving accuracy, and increasing precision.
Keya Medical has developed solutions for specialties including cardiology, radiology, neurology, pathology, and surgery. Since 2016, we have collaborated with more than 725 hospitals to improve care delivery on a global scale.
DeepVessel FFR* uses deep learning technology to perform a non-invasive physiological functional assessment of the coronary arteries using coronary CT angiogram scans. The software reduces unnecessary invasive testing to lower costs and complications.
*CE Marked, National Medical Products Administration (NMPA) Approved. Not for sale in the United States.
CuraRad® – ICH
Keya Medical is developing a comprehensive R&D pipeline to deliver clinical value throughout the patient care process. The product candidates in our pipeline will be designed for use in early screening, diagnosis, treatment, and post-treatment maintenance.
On Jan. 19, two regulatory changes went into effect that intend to modernize the Physician Self-Referral Statute & the Anti-Kickback Statute, facilitating the shift to value-based care.
Keya Medical has raised $46 million in Series D funding. This funding round was led by new and existing investors, including CICC Capital, Shanghai Artificial Intelligence Investment Fund, Qianhai Gaozu Asset Management Fund, and IN CAPITAL.
EACVI Best of Imaging introduced the latest advances in cardiac CT, promoting a patient-centric, multi-modality approach to cardiovascular disease diagnosis.